We are analyzing https://link.springer.com/article/10.1186/1741-7015-11-108.

Title:
Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials | BMC Medicine
Description:
Background Testosterone therapy is increasingly promoted. No randomized placebo-controlled trial has been implemented to assess the effect of testosterone therapy on cardiovascular events, although very high levels of androgens are thought to promote cardiovascular disease. Methods A systematic review and meta-analysis was conducted of placebo-controlled randomized trials of testosterone therapy among men lasting 12+ weeks reporting cardiovascular-related events. We searched PubMed through the end of 2012 using “(“testosterone” or “androgen”) and trial and (“random*”)” with the selection limited to studies of men in English, supplemented by a bibliographic search of the World Health Organization trial registry. Two reviewers independently searched, selected and assessed study quality with differences resolved by consensus. Two statisticians independently abstracted and analyzed data, using random or fixed effects models, as appropriate, with inverse variance weighting. Results Of 1,882 studies identified 27 trials were eligible including 2,994, mainly older, men who experienced 180 cardiovascular-related events. Testosterone therapy increased the risk of a cardiovascular-related event (odds ratio (OR) 1.54, 95% confidence interval (CI) 1.09 to 2.18). The effect of testosterone therapy varied with source of funding (P-value for interaction 0.03), but not with baseline testosterone level (P-value for interaction 0.70). In trials not funded by the pharmaceutical industry the risk of a cardiovascular-related event on testosterone therapy was greater (OR 2.06, 95% CI 1.34 to 3.17) than in pharmaceutical industry funded trials (OR 0.89, 95% CI 0.50 to 1.60). Conclusions The effects of testosterone on cardiovascular-related events varied with source of funding. Nevertheless, overall and particularly in trials not funded by the pharmaceutical industry, exogenous testosterone increased the risk of cardiovascular-related events, with corresponding implications for the use of testosterone therapy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Non-Profit & Charity
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

testosterone, pubmed, article, events, google, scholar, trials, men, cas, therapy, cardiovascularrelated, cardiovascular, randomized, study, effects, placebocontrolled, trial, risk, metaanalysis, effect, disease, adverse, clin, treatment, endocrinol, med, older, clinical, arm, systematic, review, authors, reported, analysis, androgen, additional, search, reporting, event, metab, data, industry, health, increased, low, file, figure, sci, funding, controlled,

Topics {✒️}

pubmed google scholar double-blind placebo-controlled study dual 5alpha-reductase inhibitor placebo-controlled randomized trials randomized placebo-controlled trials open access article randomized placebo-controlled trial article download pdf randomised placebo-controlled trial cardiovascular-related event rate cardiovascular-related events vary 5-mg day estrogen group symptomatic late-onset hypogonadism statistically significant meta-analyses composite cardiovascular-related events cardiovascular-related events varied long-acting testosterone treatment required medical/surgical intervention selected placebo-controlled rcts testosterone-testing advertising campaign cardiovascular-related events shown mediate cardiovascular-related events cardiovascular-related events reported pre-publication history cardiovascular-related adverse events gave treatment-related events considered cardiovascular-related death clinical intervention research system-wide composite outcome systematically searched pubmed cou-aa-301 randomised privacy choices/manage cookies placebo-controlled trials cardiovascular disease increases twelve weeks’ duration randomized controlled trials placebo-controlled trial coronary drug project randomized clinical trials bone mineral density randomized controlled trial randomised clinical trials randomized clinical trial placebo-controlled study subsequent large randomized surgical randomized trials chronic stable angina inform clinical practice clinical practice experience thromboxane promotes clotting

Questions {❓}

Bain J: Testosterone and the aging male: to treat or not to treat?
Ferreira ML, Herbert RD, Crowther MJ, Verhagen A, Sutton AJ: When is a further clinical trial justified?
Jones TH: Testosterone deficiency: a risk factor for cardiovascular disease?
Krause W, Mueller U, Mazur A: Testosterone supplementation in the aging male: which questions have been answered?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials
         description:Testosterone therapy is increasingly promoted. No randomized placebo-controlled trial has been implemented to assess the effect of testosterone therapy on cardiovascular events, although very high levels of androgens are thought to promote cardiovascular disease. A systematic review and meta-analysis was conducted of placebo-controlled randomized trials of testosterone therapy among men lasting 12+ weeks reporting cardiovascular-related events. We searched PubMed through the end of 2012 using “(“testosterone” or “androgen”) and trial and (“random*”)” with the selection limited to studies of men in English, supplemented by a bibliographic search of the World Health Organization trial registry. Two reviewers independently searched, selected and assessed study quality with differences resolved by consensus. Two statisticians independently abstracted and analyzed data, using random or fixed effects models, as appropriate, with inverse variance weighting. Of 1,882 studies identified 27 trials were eligible including 2,994, mainly older, men who experienced 180 cardiovascular-related events. Testosterone therapy increased the risk of a cardiovascular-related event (odds ratio (OR) 1.54, 95% confidence interval (CI) 1.09 to 2.18). The effect of testosterone therapy varied with source of funding (P-value for interaction 0.03), but not with baseline testosterone level (P-value for interaction 0.70). In trials not funded by the pharmaceutical industry the risk of a cardiovascular-related event on testosterone therapy was greater (OR 2.06, 95% CI 1.34 to 3.17) than in pharmaceutical industry funded trials (OR 0.89, 95% CI 0.50 to 1.60). The effects of testosterone on cardiovascular-related events varied with source of funding. Nevertheless, overall and particularly in trials not funded by the pharmaceutical industry, exogenous testosterone increased the risk of cardiovascular-related events, with corresponding implications for the use of testosterone therapy.
         datePublished:2013-04-18T00:00:00Z
         dateModified:2013-04-18T00:00:00Z
         pageStart:1
         pageEnd:12
         license:https://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1186/1741-7015-11-108
         keywords:
            Testosterone
            Cardiovascular
            Men
            Trial
            Medicine/Public Health
            general
            Biomedicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1741-7015-11-108/MediaObjects/12916_2012_Article_758_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1741-7015-11-108/MediaObjects/12916_2012_Article_758_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1741-7015-11-108/MediaObjects/12916_2012_Article_758_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1741-7015-11-108/MediaObjects/12916_2012_Article_758_Fig4_HTML.jpg
         isPartOf:
            name:BMC Medicine
            issn:
               1741-7015
            volumeNumber:11
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Lin Xu
               affiliation:
                     name:The University of Hong Kong
                     address:
                        name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Guy Freeman
               affiliation:
                     name:The University of Hong Kong
                     address:
                        name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Benjamin J Cowling
               affiliation:
                     name:The University of Hong Kong
                     address:
                        name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C Mary Schooling
               affiliation:
                     name:The University of Hong Kong
                     address:
                        name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
                        type:PostalAddress
                     type:Organization
                     name:CUNY School of Public Health at Hunter College
                     address:
                        name:CUNY School of Public Health at Hunter College, New York, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials
      description:Testosterone therapy is increasingly promoted. No randomized placebo-controlled trial has been implemented to assess the effect of testosterone therapy on cardiovascular events, although very high levels of androgens are thought to promote cardiovascular disease. A systematic review and meta-analysis was conducted of placebo-controlled randomized trials of testosterone therapy among men lasting 12+ weeks reporting cardiovascular-related events. We searched PubMed through the end of 2012 using “(“testosterone” or “androgen”) and trial and (“random*”)” with the selection limited to studies of men in English, supplemented by a bibliographic search of the World Health Organization trial registry. Two reviewers independently searched, selected and assessed study quality with differences resolved by consensus. Two statisticians independently abstracted and analyzed data, using random or fixed effects models, as appropriate, with inverse variance weighting. Of 1,882 studies identified 27 trials were eligible including 2,994, mainly older, men who experienced 180 cardiovascular-related events. Testosterone therapy increased the risk of a cardiovascular-related event (odds ratio (OR) 1.54, 95% confidence interval (CI) 1.09 to 2.18). The effect of testosterone therapy varied with source of funding (P-value for interaction 0.03), but not with baseline testosterone level (P-value for interaction 0.70). In trials not funded by the pharmaceutical industry the risk of a cardiovascular-related event on testosterone therapy was greater (OR 2.06, 95% CI 1.34 to 3.17) than in pharmaceutical industry funded trials (OR 0.89, 95% CI 0.50 to 1.60). The effects of testosterone on cardiovascular-related events varied with source of funding. Nevertheless, overall and particularly in trials not funded by the pharmaceutical industry, exogenous testosterone increased the risk of cardiovascular-related events, with corresponding implications for the use of testosterone therapy.
      datePublished:2013-04-18T00:00:00Z
      dateModified:2013-04-18T00:00:00Z
      pageStart:1
      pageEnd:12
      license:https://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1186/1741-7015-11-108
      keywords:
         Testosterone
         Cardiovascular
         Men
         Trial
         Medicine/Public Health
         general
         Biomedicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1741-7015-11-108/MediaObjects/12916_2012_Article_758_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1741-7015-11-108/MediaObjects/12916_2012_Article_758_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1741-7015-11-108/MediaObjects/12916_2012_Article_758_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1741-7015-11-108/MediaObjects/12916_2012_Article_758_Fig4_HTML.jpg
      isPartOf:
         name:BMC Medicine
         issn:
            1741-7015
         volumeNumber:11
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Lin Xu
            affiliation:
                  name:The University of Hong Kong
                  address:
                     name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Guy Freeman
            affiliation:
                  name:The University of Hong Kong
                  address:
                     name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Benjamin J Cowling
            affiliation:
                  name:The University of Hong Kong
                  address:
                     name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C Mary Schooling
            affiliation:
                  name:The University of Hong Kong
                  address:
                     name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
                     type:PostalAddress
                  type:Organization
                  name:CUNY School of Public Health at Hunter College
                  address:
                     name:CUNY School of Public Health at Hunter College, New York, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Medicine
      issn:
         1741-7015
      volumeNumber:11
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The University of Hong Kong
      address:
         name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
         type:PostalAddress
      name:The University of Hong Kong
      address:
         name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
         type:PostalAddress
      name:The University of Hong Kong
      address:
         name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
         type:PostalAddress
      name:The University of Hong Kong
      address:
         name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
         type:PostalAddress
      name:CUNY School of Public Health at Hunter College
      address:
         name:CUNY School of Public Health at Hunter College, New York, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Lin Xu
      affiliation:
            name:The University of Hong Kong
            address:
               name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
               type:PostalAddress
            type:Organization
      name:Guy Freeman
      affiliation:
            name:The University of Hong Kong
            address:
               name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
               type:PostalAddress
            type:Organization
      name:Benjamin J Cowling
      affiliation:
            name:The University of Hong Kong
            address:
               name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
               type:PostalAddress
            type:Organization
      name:C Mary Schooling
      affiliation:
            name:The University of Hong Kong
            address:
               name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
               type:PostalAddress
            type:Organization
            name:CUNY School of Public Health at Hunter College
            address:
               name:CUNY School of Public Health at Hunter College, New York, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
      name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
      name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
      name:School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, China
      name:CUNY School of Public Health at Hunter College, New York, USA

External Links {🔗}(329)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.75s.

LINK . SPRINGER . COM {}